Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas.

Launched by CENTRO DI RIFERIMENTO ONCOLOGICO - AVIANO · Feb 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how a special type of imaging called somatostatin receptor PET imaging can help doctors deliver a higher dose of radiation therapy to patients with high-risk meningiomas. Meningiomas are tumors that can develop on the membranes surrounding the brain and spinal cord, and they often require radiation treatment after surgery. The goal of this study is to see if using PET imaging to guide radiation therapy can improve the chances that the cancer doesn’t come back, while also being safe for patients.

To be eligible for the trial, participants must be at least 16 years old and have a diagnosis of either a grade III meningioma or a recurring grade II meningioma. They should not have had previous radiation treatment for their brain tumor and must be able to give informed consent. Throughout the trial, participants will receive the higher dose of radiation therapy based on the results of their PET scans, and doctors will monitor their progress closely. It’s important to note that patients who are pregnant, have other active cancer treatments, or certain types of meningiomas may not qualify for this study. Overall, the trial aims to find a more effective way to treat this challenging condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 16 years;
• • Ability to express appropriate informed consent to treatment;
• • Diagnosis of grade III meningioma (regardless of presence of residual) or diagnosis of recurrence of grade II meningioma (regardless of presence of residual) or first diagnosis of grade II meningioma with presence of residual;
• • In case of recurrence, confirmation can be either histological or radiological;
• • Not previous brain-level radiotherapy;
• • Performance status: ECOG=0-2.
• Exclusion Criteria:
• • Refusal to radiation treatment (i.e., absence of signed informed consent);
• • Other concomitant oncologic therapies
• • Current pregnancy;
• • Grade I meningiomas or Grade II meningiomas if operated on at first diagnosis with radical resection;
• • Inability to perform MRI with MoC or PET.